NASDAQ OMX

LifeSci Advisors Announces 11th Board Appointment Through Board Placement Initiative

Dela

NEW YORK, Oct. 31, 2017 (GLOBE NEWSWIRE) -- LifeSci Advisors, an investor relations and corporate communications firm focused on the life sciences sector, announced today the 11th placement of a female executive to a life sciences company board as part of its Board Placement Initiative (BPI). LifeSci Advisors launched BPI last year with the goal of connecting female executives in the life sciences industry with companies looking for board candidates. The company is pleased to share that Andrea Hunt has joined the Board of Directors of Catalyst Biosciences, (Nasdaq:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications. LifeSci Advisors will continue to make connections and look to match more candidates with open board seats in the coming months.

"I am thrilled to join the board of Catalyst Biosciences and look forward to helping them improve the lives of individuals living with hemophilia," said Ms. Hunt. "I want to thank LifeSci Advisors for facilitating this connection."

Andrea Hunt was most recently Vice President, New Product Gene Therapy, Neuroscience, Oncology & Ophthalmology at Shire Plc., where she was developing and integrating strategies for Shire's gene therapy platform. Ms. Hunt came to Shire through its acquisition of Baxalta, where she led the Global Blood Disorders Franchise within the Hematology Division. Prior to Baxalta, Ms. Hunt held several positions of increasing responsibility at Baxter Healthcare leading to her appointment as project leader to Baxter Healthcare's R&D program, BAX 855, now Adynovate(TM). Ms. Hunt served on the board for the Alliance for Regenerative Medicine and is an advisor to the Angiogenesis Foundation. Ms. Hunt earned her MBA in marketing from the University of Michigan and her B.S. in hospital dietetics and B.A. in foods and nutrition from the University of Illinois.

"We are pleased to have helped place Andrea on the Catalyst Biosciences Board, and know her expertise in hematology clinical development will be a huge asset to their team," said Michael Rice, President and Co-Founder, LifeSci Advisors. "We plan to continue the success of our Board Placement Initiative in the coming months by matching more candidates with companies and improving gender diversity at the board level across our industry."

"As a veteran of the life sciences industry, we know Andrea will bring unparalleled insight and invaluable guidance to our board," said Nassim Usman, President & Chief Executive Office, Catalyst Biosciences. "We're pleased to have her on our team as we continue the development of our hemophilia programs, and believe she will have a significant impact on the growth and success of the company."

LifeSci Advisors' Board Placement Initiative (BPI) was launched in the summer of 2016 with the goal of helping companies in the life sciences industry diversify and strengthen their company boards. Connections between companies and eligible board candidates are made after LifeSci has met with a company's management team or board regarding the skills and expertise they are looking for in a candidate, and after the LifeSci team has properly vetted the board candidates. BPI has now helped to place eleven women on corporate boards, and is looking to continue to expand upon this success. With a proprietary online network of hundreds of resumes of board-ready women, LifeSci Advisors hopes that BPI can become a resource for both women executives and life sciences companies to network and grow.

BPI is accepting resumes from interested candidates and referrals on an ongoing basis. To find out how you can use the BPI network for your next board candidate search, visit www.lifesciadvisors.com/board-diversity-initiatives. Inquiries, resume submissions, and open board seat referrals can be sent to boarddiversity@lifesciadvisors.com.

LifeSci Advisors, LLC (www.lifesciadvisors.com) is the largest investor relations consultancy in the life sciences industry, founded to provide companies with a multi-faceted approach to investor communications and outreach. With a global focus and reach, the firm provides the highest quality service for its clients through its deep sector specialization. LifeSci's team of MDs and PhDs enables the firm to better understand clients' R&D, regulatory and commercial strategies, and its team of financial services, investor relations and public relations specialists helps clients effectively communicate to the marketplace. This combination of life sciences, financial services, and investor relations competencies allows LifeSci Advisors to provide an invaluable and unique service offering to clients.

LifeSci Partners (www.lifescipartners.com) is the leading provider of consulting services in the areas of investor relations, public relations, corporate communications and capital markets advisory. Combining deep domain expertise in the life sciences with decades of experience in capital markets and public relations, LifeSci Partners delivers unparalleled services to life sciences companies globally.

For further information, please contact:

Ann Kaiser                                                                                          
The TASC Group
212-337-8870
ann@thetascgroup.com
www.thetascgroup.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: LifeSci Advisors, LLC via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Fentress Architects: The Future of Airports as Civic Spaces21.5.2018 22:27Pressmeddelande

The European Cultural Centre and Global Art Affairs Foundation invited Fentress Architects and North Carolina State University College of Design to participate in the 2018 Venice Architecture Biennale May 26-November 25, 2018, at the historic Palazzo Bembo. Denver, Colo. - May 21, 2018, May 21, 2018 (GLOBE NEWSWIRE) -- Architecture students from North Carolina State University College of Design will join Fentress at the Palazzo Bembo to present their designs for airports of the future. Fentress has been guiding students in preparation for the exhibition, which allows 11 students to embark on a once-in-a-lifetime opportunity to travel to Italy for the 2018 Venice Biennale of Architecture. Their designs will be featured in the "Time Space Existence" exhibit, offering the public a glimpse at the future of airport design. The students are participating in an Airport Design course with Principal in Charge of Design Curt Fentress, FAIA, RIBA, and Alumni Distinguished Professor of Architectur

Oxford Immunotec's T-SPOT®.TB Test Included in the World Health Organization's First-Ever Essential Diagnostics List21.5.2018 22:15Pressmeddelande

OXFORD, United Kingdom and MARLBOROUGH, Mass., May 21, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that the Company's T-SPOT.TB test for tuberculosis (TB) infection has been included in the World Health Organization (WHO) Model List of Essential In Vitro Diagnostics (EDL) - First Edition. The EDL includes the 113 most important tests recommended by WHO for use at various levels of the health care system. These essential diagnostics satisfy the priority health care needs of the population and were selected with due regard to disease prevalence and public health relevance, evidence of efficacy and accuracy, and comparative cost-effectiveness. 58 of the tests listed are for the detection and diagnosis of a wide range of common conditions, providing an essential package that can form the basis for screening and management of patients. The remaining 55 tests are designed for the detection, diagnosis, and moni

Virgin Pulse and RedBrick Health Joining Forces to Create World's Largest Digital Employee Wellbeing and Engagement Company21.5.2018 17:00Pressmeddelande

Merger Will Create First and Only One-Stop-Shop for Employee Health, Wellbeing and Benefits Engagement; Combined Company Will Have More Than 3,300 Customers Across 190 Countries PROVIDENCE, R.I., May 21, 2018 (GLOBE NEWSWIRE) -- Providence-based Virgin Pulse and Minneapolis-based RedBrick Health announced today that the industry pioneers will merge, creating the world's largest, most comprehensive digital health and engagement company. This powerful combination will deliver the industry's only fully integrated digital platform, with benefits navigation and live coaching to support global clients and members across the entire health, wellbeing and benefits lifecycle - from screening and assessment to activation, behavior change and the adoption of sustainable, healthy habits. "We are thrilled to join with RedBrick to set a new vision and standard for employee health, wellbeing and engagement," said David Osborne, Virgin Pulse CEO, who will serve as CEO of the combined company. "Bringing

Hotels.com App Wins 2018 MediaPost Appy Award in Travel & Tourism Category21.5.2018 16:00Pressmeddelande

Developed by EPAM, app is recognized for creativity and excellence in app design NEWTOWN, Pa., May 21, 2018 (GLOBE NEWSWIRE) -- Hotels.com® and EPAM Systems, Inc. (NYSE:EPAM) announced their triumphant win at the 2018 MediaPost Appy Awards in the Travel and Tourism category this week. The Hotels.com mobile app, developed in collaboration with EPAM Systems, Inc., a leading global provider of digital platform engineering and software development services, has been crowned the best app developed for airlines, hotels, travel search engines, destinations, cruises, travel advice or car rentals. With over 70 million downloads and a 4.5+ star rating from consumers on both iOS and Android app stores, the Hotels.com app has now been recognized by the industry leading Appy Awards, which honor creativity and excellence in app design. The app provides a simple, fast and secure way for users to plan, book and manage hotel reservations, and allows travelers to book hundreds of thousands of places to

Karolinska Development's portfolio company Pharmanest appoints new CEO21.5.2018 15:01Pressmeddelande

STOCKHOLM, May 21, 2018. Karolinska Development's portfolio company Pharmanest AB announces the appointment of Helena Jansson as new Chief Executive Officer. Helena is an experienced life science executive, with a proven track record of successful business development and commercialization of pharmaceutical products. She replaces Gunilla Lundmark, who leaves her position after seven years. Helena Jansson has long experience in the life science industry and a broad knowledge base with a focus on business development and commercialization of pharmaceutical portfolios. She has spent a substantial part of her career at Medivir AB, in positions such as Business Unit Director, Head of Supply Chain and Director Alliance Management. In 2017, Pharmanest signed an outlicensing agreement with Gedeon Richter, a leading European pharmaceutical company within women's health. The agreement gives Gedeon Richter the marketing and sales rights to commercialize Pharmanest's first product SHACT (Short Act

Karolinska Development's portfolio company Pharmanest appoints new CEO21.5.2018 15:01Pressmeddelande

STOCKHOLM, May 21, 2018. Karolinska Development's portfolio company Pharmanest AB announces the appointment of Helena Jansson as new Chief Executive Officer. Helena is an experienced life science executive, with a proven track record of successful business development and commercialization of pharmaceutical products. She replaces Gunilla Lundmark, who leaves her position after seven years. Helena Jansson has long experience in the life science industry and a broad knowledge base with a focus on business development and commercialization of pharmaceutical portfolios. She has spent a substantial part of her career at Medivir AB, in positions such as Business Unit Director, Head of Supply Chain and Director Alliance Management. In 2017, Pharmanest signed an outlicensing agreement with Gedeon Richter, a leading European pharmaceutical company within women's health. The agreement gives Gedeon Richter the marketing and sales rights to commercialize Pharmanest's first product SHACT (Short Act

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum